# A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

> **NCT05297565** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 14 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab/rHuPH20
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05297565
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2024-02-08
- **Final completion:** 2024-02-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297565, "A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05297565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*